Feasibility of Ayurveda in Patients With Mild-to-Moderate COVID-19: A Community-Based Participatory Research

Aarogyam UK28 enrolled

Overview

Innovative strategies are required to manage COVID-19 in the communities. Back to Roots community based project was a collaborative, pilot intervention program in British Asian community to assess the efficacy and safety of Ayurveda intervention in relieving symptoms of mild-to-moderate COVID-19.

Study Type

INTERVENTIONAL

Allocation

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

Conditions

Covid19

Interventions

AyurvedaOTHER

Dosage was used in common range (Ashwagandha: Doses range from 250 mg to 5 g; Giloy: range from 500mg to 1g; Tulsi: 500mg-1g) Dosage were altered based on age, weight and severity of symptoms.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * With SARS-CoV-2 infection confirmed through reverse transcription followed by polymerase chain reaction (RT- PCR), * With mild or moderate manifestations of COVID-19 * Willing to participate, and consent by signing the informed consent and * not involved in another clinical trial during the study Exclusion Criteria: * Patients suffering from severe COVID-19 Disease as per World Health Organisation criteria (REF) * Any of the known COVID-19 complications and emergency procedures which may require shift/admission in hospital for oxygen support or intensive care unit * Patients with ongoing immunosuppressive therapy for any reasons * Active cancer diagnosis, on palliative treatment or requiring current therapy with antimetabolic agents, immunotherapy or radiotherapy. * Pregnancy and lactation * Ayurveda practitioner decision that involvement in the study is not in the patient's best interest

Locations (1)

Aarogyam UK

Leicester, Leicestershire, United Kingdom

Outcomes

Primary Outcomes

Time to clinical recovery

To evaluate the therapeutic efficacy, mean days for clinical recovery were recorded from AiM Covid Application

Time frame: Up to 14-days

Proportion of patient with negative conversion in nasopharyngeal swab

To evaluate the therapeutic efficacy, promotion of patients were recorded through AiM Covid application

Time frame: Up to 14 days

Secondary Outcomes

Clinical Outcome

Clinical Outcome was recorded on 7-pont ordinal scale of COVID-19

Time frame: Up to 14-days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.